MAPT and Alzheimer disease: In summary, AD is a disease that progresses from an asymptomatic phase, to a minor cognitive (MCI) phase, to AD with mild, moderate, and severe dementia phases with biomarker evidence [84], including higher levels of exosomal Tau, p-Tau-181, and p-Tau-231.